WX-UK1

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H47N5O5S.ClH
Molecular Weight	650.272
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC=CC(=C2)C(N)=N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C

InChI

InChIKey=FMHIVIJVVYYSRN-JCOPYZAKSA-N

InChI=1S/C32H47N5O5S.ClH/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7;/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34);1H/t28-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C32H47N5O5S
Molecular Weight	613.811
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: DOI: 10.1158/1535-7163.TARG-17-B055 | https://clinicaltrials.gov/ct2/show/NCT00083525 | https://adisinsight.springer.com/drugs/800012176

Wilex developed WX-UK1 as a specific inhibitor of human trypsin-2, human trypsin-3 and urokinase-plasminogen activator. WX-UK1 participated in phase I clinical trial in combination with capecitabine in advanced malignancies to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics. However, in April 2014, the clinical development of this drug was discontinued, as part of a company restructure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Trypsin II 2 Target ID: CHEMBL3159 Sources: DOI: 10.1158/1535-7163.TARG-17-B055	Inhibitor 8146	75.0 nM [Ki]
Trypsin III 2 Target ID: CHEMBL4551 Sources: DOI: 10.1158/1535-7163.TARG-17-B055	Inhibitor 8146	19.0 nM [Ki]
Urokinase-type plasminogen activator 4 Target ID: P00749 Gene ID: 5328.0 Gene Symbol: PLAU Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15170662	Inhibitor 8146

PubMed

Title	Date	PubMed
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.	2003 Feb	12675525
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.	2004 Jul 20	15170662

Substance Class	Chemical Created by `admin` on `Fri Dec 16 18:28:17 UTC 2022` Edited by `admin` on `Fri Dec 16 18:28:17 UTC 2022`
Record UNII	UJ925Q0P3B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

WX-UK1

Common Name

English

Wx uk1 [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

255374-84-6